Nanotechnology in cancer therapy: targeting the inhibition of key DNA repair pathways.
Cancer therapy has been changing over the decades as we move away from the administration of broad spectrum cytotoxic drugs and towards the use of therapy targeted for each tumor type. After the induction of DNA damage through chemotherapeutic agents, tumor cells can survive due to their proficient DNA repair pathways, some of which are dysregulated in cancer. Latest improvements in nanotechnology and drug discovery has led to the discovery of some very unique, highly specific and innovative drugs as inhibitors of various DNA repair pathways like base excision repair and double strand break repair. In this review we look at the efficacy and potency of these small chemical molecules to target the processing of DNA damage induced by standard therapeutic agents. Emphasis is given to those drugs currently under clinical trials. We also discuss the future directions of using this nanotechnology to increase the therapeutic ratio in cancer treatment.
Aziz
K
K
Department of Biology, Thomas Harriot College of Arts and Sciences, East Carolina University, Greenville, NC 27858, USA.
Nowsheen
S
S
Georgakilas
A G
AG
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004249:DNA Damage; D004260:DNA Repair; D045643:DNA Repair Enzymes / Q000037:antagonists & inhibitors; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D058990:Molecular Targeted Therapy / Q000379:methods*; D050997:Nanomedicine / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011839:Radiation, Ionizing; D011840:Radiation, Nonionizing; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species; D011065:Poly(ADP-ribose) Polymerases; D045643:DNA Repair Enzymes